Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the United States Food and Drug Administration an Abbreviated New Drug Application for azelastine hydrochloride nasal spray (0.15%) and has notified Meda Pharmaceuticals Inc., the owner of the New Drug Application of its filing.
The recall involves certain bottles of the headache medicine Excedrin, NoDoz, Bufferin and Gas-X.
The government is considering whether it’s OK for young teenagers to buy emergency contraception without a prescription.
A potential drug shortage has patients and doctors worried about properly caring for their patients.
Asthma patients who rely on over-the-counter inhalers will need to switch to prescription-only alternatives as part of the federal government’s latest attempt to protect the Earth’s atmosphere.
In the most significant change to U.S. cigarette packs in 25 years, the FDA released nine new warning labels that depict in graphic detail the negative health effects of tobacco use.
Detroit-based Caraco Pharmaceutical Laboratories Inc. will shortly cease operation as a publicly traded company.
Henry Ford Hospital dermatologist Dr. Henry Lim says the government has issued stricter standards for using the term “broad spectrum.”
The Food and Drug Administration has approved another new treatment for the chronic liver disorder known as Hepatitis C.
Allegan-based Perrigo Co. (Nasdaq: PRGO) announced that it has received final approval from the United States Food and Drug Administration for its abbreviated new drug application for over-the-counter Ranitidine 150 (regular and cool mint), a generic version of Zantac 150.